A2B adenosine receptor antagonists
US6977300B2 · kind B2 · utility
37Cited by
13References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 2003 |
| Grant date | Dec 20, 2005 |
| Priority date | — |
| Expiry date | Nov 17, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.